Compare HLX & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLX | NRIX |
|---|---|---|
| Founded | 1979 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 1996 | 2020 |
| Metric | HLX | NRIX |
|---|---|---|
| Price | $10.05 | $14.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $10.50 | ★ $30.58 |
| AVG Volume (30 Days) | ★ 1.7M | 891.7K |
| Earning Date | 04-22-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $876,561,000.00 | $76,987,000.00 |
| Revenue This Year | $2.91 | N/A |
| Revenue Next Year | $4.97 | $26.32 |
| P/E Ratio | $48.02 | ★ N/A |
| Revenue Growth | 3.60 | ★ 99.31 |
| 52 Week Low | $5.52 | $8.18 |
| 52 Week High | $10.75 | $22.50 |
| Indicator | HLX | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 65.97 | 42.98 |
| Support Level | $6.20 | $11.34 |
| Resistance Level | $10.75 | $16.47 |
| Average True Range (ATR) | 0.32 | 0.85 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 92.84 | 36.53 |
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. The Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S., and it also has its presence in North Sea, Brazil, Asia Pacific, West Africa, and Other.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.